The search for circulating epilepsy biomarkers

Biomarkers in Medicine

Volumn 8, Issue 3, 2014, Pages 413-427

  Hegde, Manu ^a,b   Lowenstein, Daniel H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

autoantibodies; biomarkers; blood; cerebrospinal fluid; epilepsy epileptogenesis; inflammation; pharmacoresistance

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR; AUTOANTIBODY; BIOLOGICAL MARKER; CD133 ANTIGEN; CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; GELSOLIN; GLUCOSE TRANSPORTER 1; GLUTAMATE DECARBOXYLASE; HEAT SHOCK PROTEIN 70; HLA ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 134; MICRORNA 146A; MICRORNA 155; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID; NERVE CELL ADHESION MOLECULE; PROTEIN BCL 2; SUPEROXIDE DISMUTASE; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

CEREBROSPINAL FLUID; DISEASE COURSE; EPILEPSY; EPILEPTIC STATE; GENOTYPE; HERPES SIMPLEX; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; INFLAMMATION; LEUKOCYTE; MORBIDITY; PYRIDOXINE DEFICIENCY; REVIEW; SEIZURE; WART VIRUS; BLOOD; GENETICS; METABOLISM; PAPILLOMA VIRUS; PATHOLOGY; PHYSIOLOGY; ROSEOLOVIRUS;

AUTOANTIBODIES; BIOLOGICAL MARKERS; EPILEPSY; HUMANS; PAPILLOMAVIRIDAE; POTASSIUM CHANNELS, VOLTAGE-GATED; RECEPTORS, GABA-B; ROSEOLOVIRUS;

EID: 84898440300     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.13.142     Document Type: Review

References (97)

1. Engel J. Biomarkers in epilepsy: foreword. Biomark. Med. 5(5), 529-530 (2011).
2. Lowenstein DH. Interview: The National Institute of Neurological Diseases and Stroke/American Epilepsy Society benchmarks and research priorities for epilepsy research. Biomark. Med. 5(5), 531-535 (2011).
3. Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J. Neurol. Neurosurg. Psychiatry 83(6), 638-645 (2012).
4. Bien CG, Urbach H, Schramm J et al. Limbic encephalitis as a precipitating event in adult-onset temporal lobe epilepsy. Neurology 69(12), 1236-1244 (2007).
5. Irani SR, Bien CG, Lang B. Autoimmune epilepsies. Curr. Opin. Neurol. 24(2), 146-153 (2011).
6. Mcknight K, Jiang Y, Hart Y et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 65(11), 1730-1736 (2005).
7. Bien CG, Scheffer IE. Autoantibodies and epilepsy. Epilepsia 52, 18-22 (2011).
8. Brenner T, Sills GJ, Hart Y et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 54, 1028-1035 (2013).
9. Suleiman J, Brilot F, Lang B, Vincent A, Dale RC. Autoimmune epilepsy in children: Case series and proposed guidelines for identification. Epilepsia 54(6),1036-1045 (2013).
10. Ploune P. Benign familial neonatal seizures and benign idiopathic neonatal seizures. In: Epilepsy: A Comprehensive Textbook. Engel J, Pedley T (Eds). Lippincott Williams & Wilkins, PA, USA, 2287-2296 (2008).
11. Gu W, Brodtkorb E, Steinlein OK. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann. Neurol. 52(3), 364-367 (2002).
12. Fukata Y, Lovero KL, Iwanaga T et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc. Natl Acad. Sci. USA 107(8), 3799-3804 (2010).
13. Lai M, Huijbers MGM, Lancaster E et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 9(8), 776-785 (2010).
14. Irani SR, Michell AW, Lang B et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann. Neurol. 69(5), 892-900 (2011).
15. Liimatainen S, Peltola M, Sabater L et al. Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia 51(5), 760-767 (2010).
16. Errichiello L, Perruolo G, Pascarella A et al. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: a study on 233 patients. J. Neuroimmunol. 211(1-2), 120-123 (2009).
17. Stagg CJ, Lang B, Best JG et al. Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels. Epilepsia 51(9), 1898-1901 (2010).
18. Nociti V, Frisullo G, Tartaglione T et al. Refractory generalized seizures and cerebellar ataxia associated with anti-GAD antibodies responsive to immunosuppressive treatment. Eur. J. Neurol. 17(1), e5 (2010).
19. Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 79(11), 1094-1100 (2012).
20. Irani SR, Bera K, Waters P et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly nonparaneoplastic disorder of both sexes. Brain 133(Pt 6), 1655-1667 (2010).
21. Niehusmann P, Dalmau J, Rudlowski C et al. Diagnostic value of N-methyl-d-aspartate receptor antibodies in women with new-onset epilepsy. Arch. Neurol. 66(4), 458-464 (2009).
22. Johnson N, Henry C, Fessler AJ, Dalmau J. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology 75(16), 1480-1482 (2010).
23. Titulaer MJ, McCracken L, Gabilondo I et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 12(2), 157-165 (2013).
24. Gambardella A, Manna I, Labate A et al. GABA(B) receptor polymorphism (G1465A) is associated with temporal lobe epilepsy. Neurology 60(4), 560-563 (2003).
25. Stogmann E, Zimprich A, Baumgartner C, Gleiss A, Zimprich F. Lack of association between a GABA receptor gene polymorphism and temporal lobe epilepsy. Epilepsia 47(2), 437-439 (2006).
26. Lancaster E, Lai M, Peng X et al. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 9(1), 67-76 (2010).
27. Quek AML, Britton JW, McKeon A et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch. Neurol. 69(5), 582 (2012).
28. Fotheringham J, Donati D, Akhyani N et al. Association of human herpesvirus-6B with mesial temporal lobe epilepsy. PLoS Med. 4(5), e180 (2007).
29. Theodore WH, Epstein L, Gaillard WD, Shinnar S, Wainwright MS, Jacobson S. Human herpes virus 6B: a possible role in epilepsy? Epilepsia 49(11), 1828-1837 (2008).
30. Niehusmann P, Mittelstaedt T, Bien CG et al. Presence of human herpes virus 6 DNA exclusively in temporal lobe epilepsy brain tissue of patients with history of encephalitis. Epilepsia 51(12), 2478-2483 (2010).
31. Markowitz LE, Hariri S, Lin C et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J. Infect. Dis. 208(3), 385-393 (2013).
32. Chen J, Tsai V, Parker WE, Aronica E, Baybis M, Crino PB. Detection of human papillomavirus in human focal cortical dysplasia type IIB. Ann. Neurol. 72(6), 881-892 (2012).
33. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat. Rev. Neurol. 7(1), 31-40 (2011).
34. Ravizza T, Gagliardi B, Noe F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol. Dis. 29(1), 142-160 (2008).
35. Zattoni M, Mura ML, Deprez F et al. Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J. Neurosci. 31(11), 4037-4050 (2011).
36. Nabbout R. Autoimmune and inflammatory epilepsies. Epilepsia 53, 58-62 (2012).
37. Vezzani A, Friedman A. Brain inflammation as a biomarker in epilepsy. Biomark. Med. 5(5), 607-614 (2011). 53(7), 1113-1118 (2012).
38. Vezzani A, Friedman A, Dingledine RJ. The role of inflammation in epileptogenesis. Neuropharmacology 69(C), 16-24 (2013).
39. Zurolo E, Iyer A, Maroso M et al. Activation of Toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development. Brain 134(Pt 4), 1015-1032 (2011).
40. Omran A, Peng J, Zhang C et al. Interleukin-1β and microRNA-146a in an immature rat model and children with mesial temporal lobe epilepsy. Epilepsia 53(7), 1215-1224 (2012).
41. Maroso M, Balosso S, Ravizza T, Liu J, Bianchi ME, Vezzani A. Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1. J. Intern. Med. 270(4), 319-326 (2011).
42. Pernot F, Heinrich C, Barbier L et al. Inflammatory changes during epileptogenesis and spontaneous seizures in a mouse model of mesiotemporal lobe epilepsy. Epilepsia 52(12), 2315-2325 (2011).
43. Galanopoulou AS, Gorter JA, Cepeda C. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 53(7), 1119-1130 (2012).
44. Crino PB. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol. Med. 17(12), 734-742 (2011).
45. Franz DN, Belousova E, Sparagana S et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled Phase 3 trial. Lancet 381(9861), 125-132 (2013).
46. Krueger DA, Wilfong AA, Holland-Bouley K et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann. Neurol. doi:10.1002/ana.23960 (2013) (Epub ahead of print).
47. Serrano GE, Lelutiu N, Rojas A et al. Ablation of cyclooxygenase-2 in forebrain neurons is neuroprotective and dampens brain inflammation after status epilepticus. J. Neurosci. 31(42), 14850-14860 (2011).
48. Levin JR, Serrano G, Dingledine R. Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional neuronal deletion of cyclooxygenase-2 gene. Epilepsia 53(8), 1411-1420 (2012).
49. Shu H-F, Zhang C-Q, Yin Q, An N, Liu S-Y, Yang H. Expression of the interleukin 6 system in cortical lesions from patients with tuberous sclerosis complex and focal cortical dysplasia type IIb. J. Neuropathol. Exp. Neurol. 69(8), 838-849 (2010).
50. Lehtimäki KA, Liimatainen S, Peltola J, Arvio M. The serum level of interleukin-6 in patients with intellectual disability and refractory epilepsy. Epilepsy Res. 95(1-2), 184-187 (2011).
51. Pineda E, Shin D, You SJ, Auvin S, Sankar R, Mazarati A. Maternal immune activation promotes hippocampal kindling epileptogenesis in mice. Ann. Neurol. 74(1), 11-19 (2013).
52. Holtman L, Van Vliet EA, Aronica E, Wouters D, Wadman WJ, Gorter JA. Blood plasma inflammation markers during epileptogenesis in post-status epilepticus rat model for temporal lobe epilepsy. Epilepsia 54(4), 589-595 (2013).
53. Marchi N, Johnson AJ, Puvenna V et al. Modulation of peripheral cytotoxic cells and ictogenesis in a model of seizures. Epilepsia 52(9), 1627-1634 (2011).
54. Bauer S, Köller M, Cepok S et al. NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp. Neurol. 211(2), 370-377 (2008).
55. Rossi B, Angiari S, Zenaro E, Budui SL, Constantin G. Vascular inflammation in central nervous system diseases: adhesion receptors controlling leukocyte-endothelial interactions. J. Leukoc. Biol. 89(4), 539-556 (2011).
56. Fabene PF, Laudanna C, Constantin G. Leukocyte trafficking mechanisms in epilepsy. Mol. Immunol. 55(1), 100-104 (2013).
57. Fabene PF, Navarro Mora G, Martinello M et al. A role for leukocyte-endothelial adhesion mechanisms in epilepsy. Nat. Med. 14(12), 1377-1383 (2008).
58. Bell MD, Perry VH. Adhesion molecule expression on murine cerebral endothelium following the injection of a proinflammagen or during acute neuronal degeneration. J. Neurocytol. 24(9), 695-710 (1995).
59. Librizzi L, Regondi MC, Pastori C, Frigerio S, Frassoni C, De Curtis M. Expression of adhesion factors induced by epileptiform activity in the endothelium of the isolated guinea pig brain in vitro. Epilepsia 48(4), 743-751 (2007).
60. Louboutin J-P, Chekmasova A, Marusich E, Agrawal L, Strayer DS. Role of CCR5 and its ligands in the control of vascular inflammation and leukocyte recruitment required for acute excitotoxic seizure induction and neural damage. FASEB J. 25(2), 737-753 (2011).
61. Pollard Jr. The TARC/sICAM5 ratio in patient plasma is a candidate biomarker for drug resistant epilepsy. Front. Neurol. 3(1), 1-8 (2012).
62. Frank LM, Shinnar S, Hesdorffer DC et al. Cerebrospinal fluid findings in children with fever-associated status epilepticus: results of the consequences of prolonged febrile seizures (FEBSTAT) study. J. Pediatr. 161(6), 1169-1171. e1161 (2012).
63. Mcclelland S, Dubé CM, Yang J, Baram TZ. Epileptogenesis after prolonged febrile seizures: Mechanisms, biomarkers and therapeutic opportunities. Neurosci. Lett. 497(3), 155-162 (2011).
64. Mikkonen K, Pekkala N, Pokka T, Romner B, Uhari M, Rantala H. S100B proteins in febrile seizures. Seizure Eur. J. Epilepsy 21(2), 144-146 (2012).
65. Chang C-C, Lui C-C, Lee C-C et al. Clinical significance of serological biomarkers and neuropsychological performances in patients with temporal lobe epilepsy. BMC Neurol. 12(1)
66. Yang H, Wang D, Engelstad K et al. Glut1 deficiency syndrome and erythrocyte glucose uptake assay. Ann. Neurol. 70(6), 996-1005 (2011).
67. Yeghiazaryan NS, Zara F, Capovilla G, Brigati G, Falsaperla R, Striano P. Pyridoxine-dependent epilepsy: an underrecognised cause of intractable seizures. J. Paediatr. Child Health 48(3), e113-e115 (2010).
68. Bok LA, Struys E, Willemsen Maa P, Been JV, Jakobs C. Pyridoxine-dependent seizures in Dutch patients: diagnosis by elevated urinary alpha-aminoadipic semialdehyde levels. Arch. Dis. Child. 92(8), 687-689 (2007).
69. Plecko B, Stöckler-Ipsiroglu S, Paschke E, Erwa W, Struys EA, Jakobs C. Pipecolic acid elevation in plasma and cerebrospinal fluid of two patients with pyridoxinedependent epilepsy. Ann. Neurol. 48(1), 121-125 (2000).
70. Sadilkova K, Gospe SM, Hahn SH. Simultaneous determination of alpha-aminoadipic semialdehyde, piperideine-6-carboxylate and pipecolic acid by LC-MS/MS for pyridoxine-dependent seizures and folinic acidresponsive seizures. J. Neurosci. Methods 184(1), 136-141 (2009).
71. Mills PB, Struys E, Jakobs C et al. Mutations in antiquitin in individuals with pyridoxine-dependent seizures. Nat. Med. 12(3), 307-309 (2006).
72. Stockler S, Plecko B, Gospe J, Sidney M et al. Pyridoxine dependent epilepsy and antiquitin deficiency. Mol. Genet. Metabol. 104(1-2), 48-60 (2011).
73. Segal EB, Grinspan ZM, Mandel AM, Gospe SM Jr. Biomarkers aiding diagnosis of atypical presentation of pyridoxine-dependent epilepsy. Pediatr. Neurol. 44(4), 289-291 (2011).
74. Mills PB, Footitt EJ, Mills KA et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain 133(7), 2148-2159 (2010).
75. Chung W-H, Hung S-I, Hong H-S et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982)
76. Locharernkul C, Shotelersuk V, Hirankarn N. Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions. J. Clin. Neurosci. 18(10), 1289-1294 (2011).
77. Cheung Y-K, Cheng S-H, Chan EJM, Lo SV, Ng MHL, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 54(7), 1307-1314 (2013).
78. Hung S-I, Chung W-H, Liu Z-S et al. Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese. Pharmacogenomics 11(3), 349-356 (2010).
79. Locharernkul C, Loplumlert J, Limotai C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B. 1502 allele in Thai population. Epilepsia 49(12), 2087-2091 (2008).
80. Hu F-Y, Wu X-T, An D-M, Yan B, Stefan H, Zhou D. Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B1502 allele in Chinese Han population. Seizure 20(2), 160-162 (2011).
81. Mccormack M, Alfirevic A, Bourgeois S et al. HLA-A3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 364(12), 1134-1143 (2011).
82. Glauser TA. Biomarkers for antiepileptic drug response. Biomark. Med. 5(5), 635-641 (2011).
83. Hodges LM, Markova SM, Chinn LW et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet. Genomics 21(3), 152-161 (2011).
84. Löscher W, Delanty N. MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharmacogenomics 10(5), 711-713 (2009).
85. Ufer M, Von Stãlpnagel C, Muhle H et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet. Genomics 21(10), 624-630 (2011).
86. Hilger E, Reinthaler EM, Stogmann E et al. Lack of association between ABCC2gene variants and treatment response in epilepsy. Pharmacogenomics 13(2), 185-190 (2012).
87. Kilany A, Raouf ERA, Gaber AA et al. Elevated serum Bcl-2 in children with temporal lobe epilepsy. Seizure Eur. J. Epilepsy 21(4), 250-253 (2012).
88. Wang W, Wang L, Luo J et al. Role of a neural cell adhesion molecule found in cerebrospinal fluid as a potential biomarker for epilepsy. Neurochem. Res. 37(4), 819-825 (2012).
89. Chen D, Lu Y, Yu W et al. Clinical value of decreased superoxide dismutase 1 in patients with epilepsy. Seizure Eur. J. Epilepsy 21(7), 508-511 (2012).
90. Huttner HB, Corbeil D, Thirmeyer C et al. Increased membrane shedding - indicated by an elevation of CD133- enriched membrane particles - into the CSF in partial epilepsy. Epilepsy Res. 99(1-2), 101-106 (2012).
91. Peng X, Zhang X, Wang L et al. Gelsolin in Cerebrospinal Fluid as a Potential Biomarker of Epilepsy. Neurochem. Res. 36(12), 2250-2258 (2011).
92. He J-J, Li S, Shu H-F et al. The interleukin 17 system in cortical lesions in focal cortical dysplasias. J. Neuropathol. Exp. Neurol. 72(2), 152-163 (2013).
93. Mazzuferi M, Kumar G, Van Eyll J, Danis B, Foerch P, Kaminski RM. Nrf2 defense pathway: Experimental evidence for its protective role in epilepsy. Ann. Neurol. 74(4), 560-568 (2013).
94. Aronica E, Fluiter K, Iyer A et al. Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Eur. J. Neurosci. 31(6), 1100-1107 (2010).
95. Iyer A, Zurolo E, Prabowo A et al. MicroRNA-146a: a key regulator of astrocyte-mediated inflammatory response. PLoS ONE 7(9), e44789 (2012).
96. Jimenez-Mateos EM, Engel T, Merino-Serrais P et al. Silencing microRNA-134 produces neuroprotective and prolonged seizure-suppressive effects. Nat. Med. 18(7), 1087-1094 (2012).
97. Ashhab MU, Omran A, Kong H et al. Expressions of tumor necrosis factor alpha and microRNA-155 in immature rat model of status epilepticus and children with mesial temporal lobe epilepsy. J. Mol. Neurosci. 51(3), 950-958 (2013).